Helmholtz Gemeinschaft


Plasminogen activator inhibitor type-1 in cardiovascular disease: Status report 2001

Item Type:Article
Title:Plasminogen activator inhibitor type-1 in cardiovascular disease: Status report 2001
Creators Name:Huber, K. and Christ, G. and Wojta, J. and Gulba, D.
Abstract:Plasminogen activator inhibitor type-1 (PAI-1) is known to contribute to thrombus formation and to the development and the clinical course of acute and chronic cardiovascular disease, as well as of other arterial and venous thromboembolic diseases. Recently, an important role of elevated pretreatment levels of PAI-1 for failure of thrombolytic therapy of acute myocardial infarction has been discussed. PAI-1 plasma levels depend on the one hand on gene regulation but are related on the other hand to known risk factors of atherosclerosis like insulin resistance, diabetes or hypertriglyceridemia, respectively. Furthermore, an activated renin–angiotensin–aldosterone system (RAAS) significantly contributes to the upregulation of PAI-1 concentration via a receptor-mediated mechanism. In accordance to the known mechanisms of regulation of PAI-1 plasma levels, the use of specific agents like antidiabetic drugs, fibrates, statins, ACE inhibitors and angiotensin II type-1 receptor-blockers may contribute to the downregulation of circulating PAI-1 and, therefore, increase the fibrinolytic capacity and consecutively counteract the thrombotic tendency. To further improve the efficacy of thrombolytic therapy, a PAI-1 resistant variant of t-PA, TNK-t-PA, has been developed and is now available for acute myocardial infarction.
Keywords:Plasminogen Activator Inhibitor Type-1, Cardiovascular Disease, PAI-1-Resistance, Thrombolytic Therapy
Source:Thrombosis Research
Number:Suppl 1
Page Range:S7-S19
Date:30 September 2001
Official Publication:https://doi.org/10.1016/S0049-3848(01)00293-6
PubMed:View item in PubMed

Repository Staff Only: item control page

Open Access
MDC Library